Information  X 
Enter a valid email address

Lekoil Limited (LEK)


Wednesday 19 January, 2022

Lekoil Limited

Director Loan - update of legal claims

RNS Number : 9846Y
Lekoil Limited
19 January 2022

19  January 2022

Lekoil Limited

("LEKOIL" or the "Company")

Director Loan - update of legal claims

LEKOIL (AIM: LEK), the oil and gas exploration and production company with a focus on Nigeria and West Africa, notes that as previously announced, the recovery of the CEO loan made to Mr. Olalekan Akinyanmi is the subject of two lawsuits, one brought by the Company in the Courts of England & Wales and one brought by Mr. Akinyanmi in the Courts of New Jersey.

In respect of the Company's lawsuit brought in England & Wales, the Courts have declined to accept jurisdiction over the matter. 

In respect of the Mr. Akinyanmi's lawsuit brought in New Jersey, the Company is expecting a hearing on the relevant jurisdiction for the claims in the very near future.

Upon receipt of both judgements, the Company will update the market as to the next steps in the recovery of the CEO loan.  

The Company believes that the current outstanding balance of the CEO loan is circa US$1.5m.


The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.


For further information, please visit or contact:

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Jeff Keating / Stuart Gledhill


+44 20 3470 0470

Tennyson Securities (Joint Broker)

Peter Krens / Edward Haig-Thomas

+44 20 7186 9030


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t